MARIPOSA Study Shows Benefit of Amivantamab/Lazertinib in EGFR+ NSCLC

Nicolas Girard, MD, professor of Respiratory Medicine, Versailles Saint Quentin University, professor, head, at the Curie-Montsouris Thorax Institute, Institut Curie, discusses data from the phase 3 MARIPOSA trial (NCT04487080) of amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) vs osimertinib (Tagrisso) alone as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) harboring classical EGFR sensitizing mutations.

While osimertinib is the standard frontline therapy for approximately 15%-50% of patients with EGFR-mutant, advanced NSCLC, resistance to therapy remains an unmet need. With these data from MARIPOSA, amivantamab plus lazertinib represents a new standard of care for this patient population.

Transcription:

0:10 | MARIPOSA is a trial for patients with common EGFR-mutant non–small cell lung cancer. The standard of care is osimertinib as a single-agent. We have recently seen data that show that we can improve the outcome of patients in terms of PFS [progression-free survival] with this first-line treatment when combining osimertinib with chemotherapy in the FLAURA-2 [NCT04035486] study that was presented a few weeks ago. In FLAURA-2, [it showed that] we can reach something like a 25 month PFS with the combination.

0:42 | MARIPOSA is a chemo-free regimen with a combination of lazertinib, a third generation EGFR TKI and amivantamab, which is an EGFR MET antibody. With a combination of lazertinib plus amivantamab vs osimertinib, we reached a median PFS of 24 months. This is an improvement as compared with osimertinib for which median PFS was 17 months. At the end, this is very interesting data because we are now at this kind of level of median PFS of 2 years. We can do that either with FLAURA-2 with chemotherapy plus osimertinib or with MARIPOSA of amivantamab plus lazertinib. The advantages of MARIPOSA is that it's a chemotherapy-free regimen. We can use chemotherapy in the second-line setting. With regard to safety, this was as expected with the combination that was previously tested in the CHRYSALIS study [NCT02609776], [there were] mostly skin toxicities that need proactive management.